Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer [Yahoo! Finance]
Pharvaris N.V. - Ordinary Shares (PHVS)
Company Research
Source: Yahoo! Finance
B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the appointment of David Nassif, J.D., as Chief Financial Officer, effective April 15, 2024. In this role, he will be responsible for refining and implementing Pharvaris' corporate financial strategy and activities including financial reporting and operations. Mr. Nassif joins Pharvaris with more than 30 years of experience in financial management, strategic planning, mergers and acquisitions, investor relations, legal, and capital allocation, having held multiple executive financial management roles in development-stage, commercial-stage, public and private companies. “David expands Pharvaris' leadership capabilities as we become a late-stage biotech company with an exciting pipeline and strong commercial potential,” said Berndt Modig, Chief Executive Officer of Pharvaris. “David's experience, capabilities, and strong track record will help drive our financial strategy, deliver on key
Show less
Read more
Impact Snapshot
Event Time:
PHVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PHVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PHVS alerts
High impacting Pharvaris N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PHVS
News
- Pharvaris (NASDAQ: PHVS) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $34.00 price target on the stock.MarketBeat
- Pharvaris (NASDAQ: PHVS) had its price target lowered by analysts at Morgan Stanley from $35.00 to $34.00. They now have an "overweight" rating on the stock.MarketBeat
- Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]Yahoo! Finance
- Pharvaris (NASDAQ: PHVS) had its price target raised by analysts at JMP Securities from $49.00 to $50.00. They now have a "market outperform" rating on the stock.MarketBeat
- Pharvaris (NASDAQ: PHVS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $35.00 price target on the stock.MarketBeat
PHVS
Earnings
- 5/8/23 - Beat
PHVS
Sec Filings
- 4/23/24 - Form 144
- 4/15/24 - Form 144
- 4/12/24 - Form F-3ASR
- PHVS's page on the SEC website